Roche discontinues Fortovase
Roche announced May 18 it will discontinue the sale and distribution of its HIV therapy Fortovase (saquinavir). Roche said clinical demand for the product has declined significantly due to the availability of a higher dose (500 mg) formulation of Invirase (saquinavir mesylate). Fortovase will be discontinued during the first quarter 2006. Fortovase was originally positioned as a successor product to Invirase...
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.